Leriglitazone Clinical Trials (2026): 1 Studies for Cerebral Adrenoleukodystrophy (cALD)
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
1 Leriglitazone clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 1 indication (including Cerebral Adrenoleukodystrophy (cALD)) and 40 total planned enrollment. 1 Phase 3 Leriglitazone trial are listed. 1 Leriglitazone clinical trial is actively recruiting at 4 U.S. sites across 4 states. Most recent activity: NCT05819866 (May 2027).
Where to Participate: All Leriglitazone Trial Sites in the U.S. (4 sites across 4 states)
Every actively recruiting Leriglitazonetrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| CA | Stanford University Medical Center | Palo Alto94304-5978 | NCT05819866 | Map |
| MD | Kennedy Krieger Institute | Baltimore21205 | NCT05819866 | Map |
| MA | Massachusetts General Hospital | Boston02114 | NCT05819866 | Map |
| MN | University of Minnesota | Minneota55455 | NCT05819866 | Map |
Leriglitazone clinical trials at a glance: phase × recruitment status
| Phase | recruiting | Total |
|---|---|---|
| P3 | 1 | 1 |
Recruiting Leriglitazone clinical trials (1)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT05819866 | CALYXA Clinical Study to Assess the Efficacy and Safety of Leriglitazone in Adult Male Subjects With Cerebral Adrenoleukodystrophy | P3 | Cerebral Adrenoleukodystrophy (cALD) | 40 | Jul 2023 |
Leriglitazone pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| CALYX | NCT05819866 | P3 | recruiting | Cerebral Adrenoleukodystrophy (cALD) | 40 | — |
All Leriglitazone trials (1)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT05819866 | CALYX | A Clinical Study to Assess the Efficacy and Safety of Leriglitazone in Adult Male Subjects With Cerebral Adrenoleukodystrophy | P3 | recruiting | 40 | Minoryx Therapeutics, S.L. | Jul 2023 |
Leriglitazone clinical trials: frequently asked questions
- How many Leriglitazone clinical trials are there?
- 1 Leriglitazone clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 1 is actively recruiting participants.
- Are Leriglitazone clinical trials recruiting in 2026?
- Yes — 1 Leriglitazone trial is actively recruiting in 2026, with 4 U.S. sites across 4 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is Leriglitazone being studied for?
- Leriglitazone is being studied for Cerebral Adrenoleukodystrophy (cALD). The trials are grouped by indication on this page.
- What phase is Leriglitazone in?
- Leriglitazone clinical trials span 1 Phase 3. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Leriglitazone clinical trials?
- The lead sponsor across the most Leriglitazone trials is Minoryx Therapeutics, S.L.. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Leriglitazoneas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: